Clinical Effect of Hemocoagulase,Pantoprazole and Octreotide in the Treatment of Liver Cirrhosis Complicated with Esophageal Gastric-Fundus Variceal Bleeding
Objective To investigate the effect of Hemocoagulase,pantoprazole combined with octreotide in patients with liver cirrhosis complicated with esophageal gastric-fundus variceal bleeding(EGVB).Methods 94 patients with liver cirrhosis complicated with EGVB treated in Wenshang County People's Hospital from July 2020 to August 2023 were selected as the study objects,and were divided into a control group and an observation group according to random number table method,with 47 cases in each group.The control group was treated with octreotide injection and pantoprazole sodium for injection,and the observation group was treated with Hemocoagulase and pantoprazole for injection on the basis of the control group.The clinical efficacy,clinical related indexes,coagulation indexes and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P＜0.05).After treatment,the blood transfusion volume in the observation group was less than that in the control group,and the improvement time of hemostasis,black stool and hematemesis was shorter than that in the control group,with statistical significance(P＜0.05).After treatment,the levels of fibrinogen and D-dimer in observation group were lower than those in control group,and the differences between groups were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combined treatment of Hemocoagulase,pantoprazole and octreotide is effective in patients with liver cirrhosis complicated with EGVB,which can effectively reduce the amount of blood transfusion,shorten the time of hemostasis and symptom improvement,and improve coagulation function with high safety.
NETL
NSTL
万方数据
